Scarica l'app Stockscreener
26.56
1.37%
-0.37
Dopo l'orario di chiusura:
26.62
0.06
+0.23%
Precedente Chiudi:
$26.93
Aprire:
$27.15
Volume 24 ore:
557.41K
Relative Volume:
0.65
Capitalizzazione di mercato:
$1.47B
Reddito:
$2.50M
Utile/perdita netta:
$-131.12M
Rapporto P/E:
-9.3419
EPS:
-2.8431
Flusso di cassa netto:
$-112.73M
1 W Prestazione:
+2.35%
1M Prestazione:
-7.49%
6M Prestazione:
-12.26%
1 anno Prestazione:
+154.89%
Intervallo 1D:
$26.12
$27.58
Intervallo di 1 settimana:
$25.08
$28.18
Portata 52W:
$8.245
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Nome
Maze Therapeutics Inc
Settore
Industria
Telefono
(650) 850-5070
Indirizzo
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
26.56 | 1.49B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Iniziato | Truist | Buy |
| 2026-03-10 | Iniziato | Mizuho | Outperform |
| 2025-12-04 | Iniziato | Wells Fargo | Overweight |
| 2025-11-14 | Iniziato | Raymond James | Outperform |
| 2025-09-02 | Iniziato | BTIG Research | Buy |
| 2025-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Maze Therapeutics (MAZE) CSBO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan
MAZE Stock Price, Quote & Chart | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill
MAZE SEC FilingsMaze Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
After plunging 30.8% in 4 weeks, here's why the trend might reverse for Maze Therapeutics, Inc. (MAZE) - MSN
Maze Therapeutics (NASDAQ: MAZE) details 2026 proxy, board slate and executive pay - Stock Titan
Maze Therapeutics (MAZE) price target increased by 19.51% to 61.71 - MSN
Maze Therapeutics Stock Surges with 150 Percent Upside Potential - HarianBasis.co
What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy - Yahoo Finance
5 Oversold Small Cap Stocks to Buy Now - Insider Monkey
Maze Therapeutics shares surge after positive Phase 2 data for MZE829 - MSN
Maze Therapeutics Raises Fresh Capital As R&D Plans And Valuation Diverge - Sahm
Maze Therapeutics falls despite positive mid-stage trial data for lead asset - MSN
Maze Therapeutics prices $150M equity offering - MSN
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN
Maze Therapeutics prices $150 million equity offering - TipRanks
Maze Therapeutics prices $150M registered offering; expects ~$144.7M net proceeds, funds into 2029 - TradingView
[8-K] Maze Therapeutics, Inc. Reports Material Event - Stock Titan
[424B5] Maze Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Maze Therapeutics (NASDAQ:MAZE) Shares Gap UpHere's Why - MarketBeat
Maze Therapeutics (MAZE) Stock: Momentum Shift Insight (Rocket Higher) 2026-04-22Professional Trade Ideas - UBND thành phố Hải Phòng
MAZE Secures Investment from Notable Funds - GuruFocus
Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50 - TipRanks
Maze Therapeutics Intends to Use Any Net Proceeds From Offering to Advance R&D of Its Product Candidates >MAZE - Moomoo
Maze Therapeutics Prices Public Offering of 5,540,000 Shares at $23.50 Per Share, Aiming for $150 Million in Gross Proceeds - Quiver Quantitative
Maze Therapeutics announces $150 million registered offering - marketscreener.com
Maze Therapeutics Announces $150 Million Registered Offering - TradingView
Fenwick Represents Maze Therapeutics in $150M Underwritten Offering - fenwick.com
239,994 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Mass General Brigham Inc - MarketBeat
Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact - Insider Monkey
Is Maze Therapeutics (MAZE) stock holding its gains (-0.96%) 2026-04-20High Volume Stocks - UBND thành phố Hải Phòng
Maze Therapeutics (NASDAQ:MAZE) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Exploring a 139.88% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Immuneering (IMRX) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Maze Therapeutics Inc. places pharma partnerships in focus as President of R and D moderates Boston panel - Traders Union
What analysts say about Maze Therapeutics Inc stockWeekly Gains Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
MAZE Options Volatility — NASDAQ:MAZE - TradingView
MAZE Options Chain — NASDAQ:MAZE - TradingView
MAZE News Today | Why did Maze Therapeutics stock go up today? - MarketBeat
Gainers Report: Is CLVT a play on infrastructure spending2026 Selloffs & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Assessing Maze Therapeutics (MAZE) Valuation After Strong One Year Return And Recent Pullbacks - Sahm
Rally Mode: Whats the fair value of Maze Therapeutics Inc stockWeekly Loss Report & Precise Trade Entry Recommendations - baoquankhu1.vn
HC Wainwright Issues Optimistic Estimate for MAZE Earnings - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history - Yahoo Finance Australia
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial - Streetwise Reports
Are insiders buying or selling Maze Therapeutics (MAZE) Stock | Price at $28.23, Down 0.35%Community Buy Alerts - Cổng thông tin điện tử tỉnh Tây Ninh
Here is why Maze Therapeutics (MAZE) is Among the Top 8 Oversold Strong Buy-Rated Stocks - Insider Monkey
Pharma News: What analysts say about Maze Therapeutics Inc stock2026 Review & Daily Stock Momentum Reports - baoquankhu1.vn
Edison Issues Report on MindMaze Therapeutics (MMTX) - Yahoo Finance
Maze Therapeutics Inc Azioni (MAZE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):